Benzinga | May 18, 2021 08:17AM EDT

NLS Pharmaceutics Announces New Study Data Confirming Mazindol's 'Unique Orexin Pathway Activation for Treating Narcolepsy'

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))))) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces new study data which support the mechanism of action for mazindol, the active compound in the Company's lead product candidate to treat narcolepsy, Quilience(r). Narcolepsy is caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle. The new data confirm mazindol's Orexin-2 receptor (OX2R) agonist activity.